<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6426">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755403</url>
  </required_header>
  <id_info>
    <org_study_id>CINEBENZ</org_study_id>
    <nct_id>NCT01755403</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease</brief_title>
  <acronym>CINEBENZ</acronym>
  <official_title>Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barcelona Centre for International Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barcelona Centre for International Health Research</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      o study population pharmacokinetics in Benznidazole-treated adult patients with Chronic
      Chagas Disease to get information to optimize drug doses.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Population pharmacokinetic parameters of Benznidazole</measure>
    <time_frame>2 months (treatment period)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Population pharmacokinetic model development</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>2 months (treatment period)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events. Severity of adverse events. Relationship between adverse event and drug concentration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <arm_group_label>Benznidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive
             serological tests.

          -  Patients with Chronic Chagas Disease who are going to start treatment with
             Benznidazole.

          -  Any gender.

          -  All the participants must agree to participate in the study and must sign the
             informed consent.

        Exclusion Criteria:

          -  Patients younger than 18.

          -  Patients with previous hypersensitivity to Benznidazole.

          -  Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need,
             primary immunodeficiency, or any other.

          -  Hepatic dysfunction

          -  Renal dysfunction: serum creatinin higher than 3 mg/dl.

          -  Pregnancy or lactation.

          -  Low adhesion to treatment or check-up.

          -  Impossibility of follow-up.

          -  Severe adverse reaction to Benznidazole.

          -  Any other situation that could be risky for the patient.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim Gascón, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barcelona Centre for International Health Research (CRESIB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Health Department, Hospital Clinic, Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 8, 2013</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
